New: Introducing the Finviz Crypto Map

Assembly Biosciences, Inc.

Contributing Author

Recent Articles by Assembly Biosciences, Inc.

Aug-08	Assembly Biosciences Announces Pricing of $175 Million in Equity Financings ASMB +12.96% GlobeNewswire
Aug-08	Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes ASMB +12.96% GlobeNewswire
Aug-06	Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates ASMB GlobeNewswire
Aug-06	Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus ASMB GlobeNewswire
Jul-26	Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop ASMB GlobeNewswire
Jun-30	Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179 ASMB GlobeNewswire
Jun-25	Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B ASMB GlobeNewswire
May-27	Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference ASMB GlobeNewswire
May-08	Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates ASMB GlobeNewswire
May-07	New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 ASMB GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.